[go: up one dir, main page]

CL2017001943A1 - Terapias de combinación para el tratamiento de cánceres - Google Patents

Terapias de combinación para el tratamiento de cánceres

Info

Publication number
CL2017001943A1
CL2017001943A1 CL2017001943A CL2017001943A CL2017001943A1 CL 2017001943 A1 CL2017001943 A1 CL 2017001943A1 CL 2017001943 A CL2017001943 A CL 2017001943A CL 2017001943 A CL2017001943 A CL 2017001943A CL 2017001943 A1 CL2017001943 A1 CL 2017001943A1
Authority
CL
Chile
Prior art keywords
treatment
cancers
combination therapies
malignities
entospletinib
Prior art date
Application number
CL2017001943A
Other languages
English (en)
Inventor
Paolo Julie A Di
Randall Mark Jones
Daniel B Tumas
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55398445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001943(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CL2017001943A1 publication Critical patent/CL2017001943A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>SE PROPORCIONAN EN EL PRESENTE DOCUMENTO MÉTODOS QUE SE RELACIONAN CON UNA ESTRATEGIA TERAPÉUTICA PARA EL TRATAMIENTO DEL CÁNCER, INCLUYENDO MALIGNIDADES HEMATOLÓGICAS. EN PARTICULAR, LOS MÉTODOS INCLUYEN LA ADMINISTRACIÓN DE ENTOSPLETINIB Y UN INHIBIDOR DE BCL-2, TAL COMO VENETOCLAX, NAVITOCLAX Y ABT-737.</p>
CL2017001943A 2015-02-03 2017-07-28 Terapias de combinación para el tratamiento de cánceres CL2017001943A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562111604P 2015-02-03 2015-02-03

Publications (1)

Publication Number Publication Date
CL2017001943A1 true CL2017001943A1 (es) 2018-03-02

Family

ID=55398445

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001943A CL2017001943A1 (es) 2015-02-03 2017-07-28 Terapias de combinación para el tratamiento de cánceres

Country Status (25)

Country Link
US (2) US20160220573A1 (es)
EP (1) EP3253385A1 (es)
JP (1) JP2018503653A (es)
KR (1) KR20170104616A (es)
CN (1) CN107205992A (es)
AU (1) AU2016215643A1 (es)
BR (1) BR112017016019A2 (es)
CA (1) CA2974828A1 (es)
CL (1) CL2017001943A1 (es)
CO (1) CO2017007662A2 (es)
CR (1) CR20170352A (es)
CU (1) CU20170099A7 (es)
EA (1) EA201791516A1 (es)
EC (1) ECSP17048849A (es)
GT (1) GT201700167A (es)
IL (1) IL253573A0 (es)
MA (1) MA41449A (es)
MD (1) MD20170073A2 (es)
MX (1) MX2017009724A (es)
PE (1) PE20171241A1 (es)
PH (1) PH12017550063A1 (es)
SG (1) SG11201706107SA (es)
SV (1) SV2017005489A (es)
TW (1) TW201639573A (es)
WO (1) WO2016126552A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068258A1 (en) 2008-12-08 2010-06-17 Cgi Pharmaceuticals, Inc. Imidazopyrazine syk inhibitors
MX350010B (es) 2010-03-11 2017-08-23 Gilead Connecticut Inc Inhibidores syk de imidazopiridinas.
NZ715776A (en) * 2013-07-30 2017-04-28 Gilead Connecticut Inc Polymorph of syk inhibitors
CA2919479C (en) 2013-07-31 2017-08-22 Gilead Sciences, Inc. Syk inhibitors
EP3076976B1 (en) 2013-12-04 2020-09-02 Gilead Sciences, Inc. Methods for treating cancers
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
MX2017000610A (es) 2014-07-14 2017-04-27 Gilead Sciences Inc Metodos combinados para tratar canceres.
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018053190A1 (en) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Syk inhibitors
US10759798B2 (en) * 2016-09-14 2020-09-01 Hangzhou Solipharma Co., Ltd. ABT-199 addition salt and crystal form thereof, preparation method thereof, and pharmaceutical composition thereof
WO2018200841A1 (en) * 2017-04-28 2018-11-01 Actinium Pharmaceuticals, Inc. Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
US11384082B2 (en) 2017-08-25 2022-07-12 Kronos Bio, Inc. Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors
WO2019139902A1 (en) 2018-01-10 2019-07-18 Zeno Royalties & Milestones, LLC Benzamide compounds
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式
KR20220034782A (ko) 2019-06-12 2022-03-18 주노 쎄러퓨티크스 인코퍼레이티드 세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법
CN112891353B (zh) * 2019-12-04 2024-01-30 苏州亚盛药业有限公司 药物组合及其用途
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
EP4316494A4 (en) * 2021-04-05 2025-04-09 Pinotbio, Inc. COMBINED THERAPY OF 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND VENETOCLAX
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
GB0326780D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
HRP20161751T1 (hr) 2004-05-13 2017-04-07 Icos Corporation Kinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
CA2606147C (en) 2005-05-12 2011-07-05 Abbott Laboratories Apoptosis promoters
EP2185198B1 (en) 2007-08-02 2015-01-14 Gilead Biologics, Inc. Lox and l0xl2 inhibitors and uses thereof
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
US8450321B2 (en) * 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
LT2716157T (lt) * 2008-12-08 2016-09-12 Gilead Connecticut, Inc. Imidazopirazino syk inhibitoriai
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
EP2477972A1 (en) 2009-09-20 2012-07-25 Abbott Laboratories Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
RU2015108348A (ru) 2010-02-04 2015-07-20 Джилид Байолоджикс, Инк. Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
NZ701444A (en) 2010-08-27 2016-06-24 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
JP6101205B2 (ja) 2011-08-23 2017-03-22 中外製薬株式会社 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
JP2014528451A (ja) 2011-10-04 2014-10-27 ギリアード カリストガ エルエルシー Ｐｉ３ｋの新規キノキサリン阻害剤
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
AU2013302617A1 (en) * 2012-08-14 2015-02-05 Gilead Calistoga Llc Combination therapies for treating cancer
HK1212240A1 (en) * 2012-09-07 2016-06-10 吉宁特有限公司 Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
TW201427995A (zh) 2012-09-24 2014-07-16 Gilead Sciences Inc 抗ｄｄｒ１抗體
CA2895782C (en) 2012-12-21 2017-08-22 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
EP2935246B1 (en) 2012-12-21 2018-07-25 Gilead Calistoga LLC Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
PL3008053T3 (pl) 2013-06-14 2018-08-31 Gilead Calistoga Llc Inhibitory 3-kinazy fosfatydyloinozytolu
NZ715776A (en) 2013-07-30 2017-04-28 Gilead Connecticut Inc Polymorph of syk inhibitors
JP6153667B2 (ja) 2013-07-30 2017-06-28 ギリアード コネチカット， インコーポレイテッド Ｓｋｙ阻害剤の製剤

Also Published As

Publication number Publication date
KR20170104616A (ko) 2017-09-15
BR112017016019A2 (pt) 2018-03-20
US20160220573A1 (en) 2016-08-04
IL253573A0 (en) 2017-09-28
MD20170073A2 (ro) 2018-02-28
CO2017007662A2 (es) 2017-10-20
ECSP17048849A (es) 2017-10-31
PE20171241A1 (es) 2017-08-24
CR20170352A (es) 2017-09-29
MX2017009724A (es) 2017-11-17
CN107205992A (zh) 2017-09-26
CU20170099A7 (es) 2018-03-13
GT201700167A (es) 2017-11-02
WO2016126552A1 (en) 2016-08-11
US20180117052A1 (en) 2018-05-03
MA41449A (fr) 2017-12-12
AU2016215643A1 (en) 2017-08-10
PH12017550063A1 (en) 2018-02-05
JP2018503653A (ja) 2018-02-08
EP3253385A1 (en) 2017-12-13
TW201639573A (zh) 2016-11-16
SV2017005489A (es) 2017-10-17
EA201791516A1 (ru) 2018-01-31
SG11201706107SA (en) 2017-08-30
CA2974828A1 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
CL2017001943A1 (es) Terapias de combinación para el tratamiento de cánceres
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
CO2017011197A2 (es) Terapia de combinación fgfr/pd-1 para el tratamiento del cancer
UY36075A (es) Derivados de tubulisina
CR20150316A (es) Compuestos y sus métodos de empleo
MX2020001550A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
MX2015010312A (es) Metodos para tratamiento del melanoma.
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
MX384175B (es) Métodos para seleccionar una línea de células t y el donador de la misma para terapia celular adoptiva.
CL2017000391A1 (es) Nitrógeno tricíclico que contiene compuestos para el tratamiento de una infección por neisseria gonorrhoea
CL2017000050A1 (es) Terapia de combinación para el cáncer
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
NI201500063A (es) Tratamiento de cáncer con pomalidomida en un individuo con daño renal
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
MX2017011018A (es) Inhibicion de la actividad de olig2.
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
MX2016002307A (es) Tratamiento para el cancer.
GT201400071A (es) Combinación terapéutica para el tratamiento de cáncer
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa